Managing the Complicated Hypertensive Patient
|
|
- Lee Bradley
- 6 years ago
- Views:
Transcription
1 Managing the Complicated Hypertensive Patient Cheryl L. Laffer, MD, PhD, FAHA Associate Professor of Medicine, Texas A&M HSC College of Medicine Senior Staff, S&W Hypertension - Internal Medicine Vice President (Texas Chapter) and Specialist in Clinical Hypertension, American Society of Hypertension
2 Lifetime Risk of Developing Hypertension Beginning at Age Risk of hypertension (%) Men Years Women Framingham: people with blood pressure <140/90 mmhg at age 65 Vasan RS et al. JAMA. 2002; 287:1003
3
4 Latest NHANES Data: p<0.05 for all prevalence, but first in # uncontrolled & average: 143/80 to 135/74 JAMA 2010;303:2043
5 NHANES: 45% of US adults have Hypertension, Dyslipidemia or Diabetes - Highest in Blacks NCHS Data Brief 2010;10:36
6 JNC7 Express: JAMA 2003;289:2534
7 JNC7 Blood Pressure Classification BP Classification SBP mmhg DBP mmhg Normal <120 and <80 Prehypertension or Stage or Stage 2 >160 or >100 JAMA 2003;289:2560
8 Office BP Measurement Use auscultatory method with a properly calibrated and validated instrument. Patient should be seated quietly for 5 minutes in a chair (not on the exam table), feet on the floor, arm supported at heart level. Appropriate-sized cuff should be used to ensure accuracy. At least two measurements should be made. Check in other arm (once), confirm at 1 month (unless Stage 2).
9 JNC-Recommended Initial Tests Routine Tests Electrocardiogram Urinalysis Blood count (hematocrit) Serum glucose, potassium, calcium and creatinine, or the corresponding estimated GFR, Lipid profile, after 12-hour fast, that includes high-density and low-density lipoprotein cholesterol, and triglycerides Optional tests Measurement of urinary albumin excretion or albumin/creatinine ratio More extensive testing for identifiable causes is not generally indicated unless BP control is not achieved
10 JNC7 Hypertension Treatment Algorithm Lifestyle Modifications Not at Goal Blood Pressure (<140/90 mmhg) (<130/80 mmhg for those with diabetes or chronic kidney disease) Without Compelling Indications Initial Drug Choices With Compelling Indications Stage 1 Hypertension (SBP or DBP 90 99) Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Stage 2 Hypertension (SBP >160 or DBP >100) 2-drug combination for most (usually thiazide-type diuretic+ ACEI, or ARB, or BB, or CCB) Drug(s) for the compelling indications Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed. Not at Goal Blood Pressure Optimize dosages or add additional drugs until goal blood pressure is achieved. Consider consultation with hypertension specialist. JNC7. JAMA 2003;289:2560
11 Efficacious Lifestyle Modification Salt sdmnf Salt abc Weight: 1 kg = 1.6/1.3 mmhg Achieve <15% above ideal Na intake: 100 meq = 5.4/6.5 mmhg SBP 8-14 mm: DASH diet mg Na Achieve 4-6 g salt/day ( meq Na) Shopping smart EtOH to 30 cc = 1 oz / day whiskey 3 oz, wine 10 oz, beer 24 oz; half in women Exercise aerobics 30 min 5-6 x / wk = 4-9 mm SBP
12 SBP-lowering with DASH diet + Na DASH: Sacks et al. NEJM 2001;344:3
13 Effect of DASH-Na Diet on Systolic / Age Sacks & Campos. NEJM 2010;362:2102
14 JNC7 Hypertension Treatment Algorithm Lifestyle Modifications Not at Goal Blood Pressure (<140/90 mmhg) (<130/80 mmhg for those with diabetes or chronic kidney disease) Without Compelling Indications Initial Drug Choices With Compelling Indications Stage 1 Hypertension (SBP or DBP 90 99) Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Stage 2 Hypertension (SBP >160 or DBP >100) 2-drug combination for most (usually thiazide-type diuretic + ACEI / ARB / BB / CCB) Drug(s) for the compelling indications Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed. Not at Goal Blood Pressure Optimize dosages or add additional drugs until goal blood pressure is achieved. Consider consultation with hypertension specialist. JNC7. JAMA 2003;289:2560
15 ALLHAT: Primary Endpoint and Subgroups Combined CHD deaths and nonfatal MI, Relative Risk (95% CI) Total 0.98 ( ) 0.99 ( ) Age < ( ) 0.95 ( ) Age ( ) 1.01 ( ) Men 0.98 ( ) 0.94 ( ) Women 0.99 ( ) 1.06 ( ) Black 1.01 ( ) 1.10 ( ) Nonblack 0.97 ( ) 0.94 ( ) Diabetic 0.99 ( ) 1.00 ( ) Nondiabetic 0.97 ( ) 0.99 ( ) Favors Amlodipine Favors Chlorthalidone Favors Lisinopril Favors Chlorthalidone JAMA 2002;288:
16 JNC7 Hypertension Treatment Algorithm Lifestyle Modifications Not at Goal Blood Pressure (<140/90 mmhg) (<130/80 mmhg for those with diabetes or chronic kidney disease) Without Compelling Indications Initial Drug Choices With Compelling Indications Stage 1 Hypertension (SBP or DBP 90 99) Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Stage 2 Hypertension (SBP >160 or DBP >100) 2-drug combination for most (usually thiazide-type diuretic + ACEI, or ARB, or BB, or CCB) Drug(s) for the compelling indications Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed. Not at Goal Blood Pressure Optimize dosages or add additional drugs until goal blood pressure is achieved. Consider consultation with hypertension specialist. JNC7. JAMA 2003;289:2560
17 Compelling Indications for Individual Classes Compelling Indication Initial Therapy Options Clinical Trial Basis Heart failure THIAZ, BB, ACEI, ARB, ALDO ANT ACC/AHA Heart Failure Guideline, MERIT-HF, COPERNICUS, CIBIS, SOLVD, AIRE, TRACE, ValHEFT, RALES Postmyocardial infarction High CAD risk BB, ACEI, ALDO ANT THIAZ, BB, ACE, CCB ACC/AHA Post-MI Guideline, BHAT, SAVE Capricorn, EPHESUS ALLHAT, HOPE, LIFE, ANBP2, CONVINCE JNC7. JAMA 2003;289:2560
18 Compelling Indications for Individual Compelling Indication Initial Therapy Options Clinical Trial Basis Diabetes Classes THIAZ, BB, ACEI, ARB, CCB NKF-ADA Guideline, UKPDS, ALLHAT Chronic Kidney Disease ACEI, ARB NKF-ADA Guideline, Captopril Trial, RENAAL, IDNT, REIN, AASK Recurrent Stroke Prevention THIAZ + ACEI PROGRESS JNC7. JAMA 2003;289:2560
19 JNC7 Hypertension Treatment Algorithm Lifestyle Modifications Not at Goal Blood Pressure (<140/90 mmhg) (<130/80 mmhg for those with diabetes or chronic kidney disease) Without Compelling Indications Initial Drug Choices With Compelling Indications Stage 1 Hypertension (SBP or DBP 90 99) Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Stage 2 Hypertension (SBP >160 or DBP >100) 2-drug combination for most (usually thiazide-type diuretic + ACEI, or ARB, or BB, or CCB) Drug(s) for the compelling indications Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed. Not at Goal Blood Pressure Optimize dosages or add additional drugs until goal blood pressure is achieved. Consider consultation with hypertension specialist. It s on NextGen! JNC7. JAMA 2003;289:2560
20 Hypertension in High-Risk Patients: Number of Agents Needed UKPDS (<85 mm Hg, diastolic) MDRD (92 mm Hg, MAP) HOT (<80 mm Hg, diastolic) AASK (<92 mm Hg, MAP) RENAAL (<140/90 mm Hg) IDNT ( <135/85 mm Hg) 1 average 2 3 Number of BP Medications UKPDS=United Kingdom Prospective Diabetes Study; MDRD=Modification of Diet in Renal Disease; HOT=Hypertension Optimal Treatment; AASK=African American Study of Kidney Disease; RENAAL=Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan; IDNT=Irbesartan Diabetic Nephropathy Trial. 4
21 (a brief reminder)
22 Sites of Action of Major Antihypertensive Drug Classes Diuretics -Blockers + Kidney tubules (Na/Ca) Calcium Channel / a 1 Blockers (vasodilators) Vascular smooth muscle Heart DRI ACEIs ARBs Kidney JGA Renin Angiotensin I Angiotensin II x x x AT 1 receptors Renin-Angio-Aldo System
23 Diuretics (Thiazide-like) Benefits Reduce CHD mortality CHF ( incidence & progression: ALLHAT) Additive effect with most other classes Isolated Systolic H (SHEP) Decrease nephrolithiasis and osteoporotic hip fractures Reversal of LVH Limitations NSAIDs / hi Na interfere Mg, K, Na [elderly] glucose & TChol+TG (short-term: TOMHS) ±ED Ca & uric acid (usually asymptomatic, but both sustained) All worse with HCTZ>50 or chlorthalidone>25 mg daily JNC7. JAMA 2003;289:2560
24 Patients With Hypertension Are Likely to Be Treated With NSAIDs Up to 36% (18 million) of adults with hypertension also have osteoarthritis 1 12 million patients receiving NSAIDs for treatment of osteoarthritis are also being treated with antihypertensive medication 2 NSAID use is highest in the elderly, the segment of the population with the highest prevalence of hypertension 2 In addition to their effects on salt, they increase daily production of ET-1 by 83% 1. Blake. Am Fam Physician. 1994;50:138, 2. Ruoff. Clin Ther. 1998;20:376, 3. Johnson. J Hum Hypertens 1996;10:257
25 Incidence of Clinically Meaningful BP Elevation with COX-II inhibitors Study 1 1 Study 2 2 Celecoxib 200 mg qd (n=411) (n=549) Study 1 1 Study 2 2 Rofecoxib 25 mg qd (n=399) (n=543) Percentage of Patients p=0.03 p< SBP >20 mm Hg and >140 mm Hg ns ns DBP >15 mm Hg and >90 mm Hg 1.Whelton et al. Am J Ther 2001;8:85, 2.Data on file, Pfizer
26 Sites of Action of Major Antihypertensive Drug Classes Diuretics -Blockers + Kidney tubules Calcium Channel / a 1 Blockers (vasodilators) Vascular smooth muscle Heart DRI ACEIs ARBs Kidney JGA Renin Angiotensin I Angiotensin II x x x AT 1 receptors Renin-Angio-Aldo System
27 Beta - Blockers Benefits Anti-anginal Post-MI prophylaxis (secondary prevention) LV systolic dysfunction Reversal of LVH, but less than other classes Combined ab blockers (labetalol / carvedilol) appear to benefit without limitations Limitations Lipids: HDL TG Worsen insulin resistance [not ab: GEMINI] Asthma (bronchospasm with less b1-selective - caution in COPD) PAD / ED / >1 AVB Exercise-intolerance Down-titrate Benowitz 1995; JNC7 2003
28 -Blockers and Clinical Outcomes Relative Risk Other antihypertensives All -blockers Placebo All-Cause Mortality Stroke Myocardial Infarction All-Cause Mortality Lindholm et al. Lancet 2005;366:1545
29 Should beta-blockers remain first-line therapy? 2006: UK (NICE: National Institute for health & Clinical Excellence) removes them as 1/2/3 rd -line Rx of uncomplicated hypertension (ASCOT, LIFE, etc.) NICE recommends thiazide or CCB as first line in most (older, blacks, ) otherwise ACE-inhibitor European guideline updates in 2007 & 09 did not concur, latest emphasizes individualized Rx What will happen in JNC8?
30 Sites of Action of Major Antihypertensive Drug Classes Diuretics -Blockers + Kidney tubules Calcium Channel / a 1 Blockers (vasodilators) Vascular smooth muscle Heart DRI ACEIs ARBs Kidney JGA Renin Angiotensin I Angiotensin II x x x AT 1 receptors Renin-Angio-Aldo System
31 ACE-Inhibitors / ARBs (DRI) Benefits Systolic CHF post-mi Improve insulin sensitivity [Micardis: PPARg agonist] Protect / prevent (non/&) diabetic nephropathy Stroke prevention (losartan vs atenolol - LIFE trial) Reversal of LVH (best?) No adverse lipid effects Limitations ACEIs: angioedema / cough hypotension: with volume depletion [don t STOP] Hyperkalemia (CKD / NSAIDs / Diab RTA4) Pregnancy (second-trim: to aldomet / labetalol) Bilat renal artery stenosis Benowitz 1995; JNC7 2003
32 Sites of Action of Major Antihypertensive Drug Classes Diuretics -Blockers + Kidney tubules Calcium Channel / a 1 Blockers (vasodilators) Vascular smooth muscle Heart DRI ACEIs ARBs Kidney JGA Renin Angiotensin I Angiotensin II x x x AT 1 receptors Renin-Angio-Aldo System
33 Calcium-Channel Blockers Benefits Anti-anginal Isolated Systolic Htn (DHP: CVA & mortality: Syst-Eur) Work in low-renin states Neutral lipids / DM Reversal of LVH Limitations Short-acting may - mortality* Constipation (V/D) / tachycardia, flushing, edema (DHP) Caution with CHF JNC7 2003; *Furberg Am J Hypertens 1996;9:122
34 Alpha-1 Blockers Benefits Lipids: HDL LDL TG net: Chol/HDL - unique Improve insulin sensitivity Relaxation of bladder sphincter (BPH) Reversal of LVH No reduction in C.O. No adverse renal / pulmonary effects Limitations First-dose effect: orthostatic hypotension (visceral pooling) - initiate h.s. Worsening of stress urinary incontinence (elderly F) Rare exacerbation of angina (small vessel constriction) Nasal stuffiness CHF (vs chlorthalidone ALLHAT)
35 Fourth Line
36 Centrally-Acting Alpha 2 Agonists CLONIDINE GUANABENZ / GUANFACINE Brainstem stimulation: a 2 receptors + imidazole receptors (clonidine) Peripheral stimulation: a 1 and presyn a 2 receptors SNS Activity Vagal Tone HR Norepinephrine Renin release NET: TPR+ CO = BP Acute withdrawal associated with BP rebound at moderate doses Side effects (diminish with time): dry mouth, drowsy, dizzy, constipated, sedated
37 When all else fails: Direct Vasodilators, but VASODILATOR DIURETIC Vasodilation Peripheral Resistance Arterial Pressure Sodium Retention Renin Release Fluid Volume Angiotensin Aldosterone Vasoconstriction SYMPATHETIC BLOCKER SNS Activity Norepinephrine Heart Rate & Contractility Venous Compliance Cardiac Output TPR MINOXIDIL: vsm K-channel opener (±) hair growth, rare pericardial effusion HYDRALAZINE resistance artery vasorelaxant (-) lupus-like reaction, vasculitis Koch-Weser. Arch Intern Med 1974;133:1017
38
39 Renin Profiling: U Na V and PRA PRA (nga I /ml/hr) % below lower 95% CI UNaV (meq/24 hrs) Laffer CL, Elijovich F. J Clin Hypertens 2002;4:266
40 Effects of Different Antihypertensives on BP of Caribbean Hispanic Subjects Systolic BP (mmhg) Diastolic BP (mmhg) * * * Placebo, n=14 ACE Inh, n=24 Ca ++ Blocker, n=10 bblocker, n=13 HCTZ, n=18 *, : significant vs placebo * * * HCTZ+ACE Inh, n=13 HCTZ+bBlocker, n=14 Laffer & Elijovich. J Clin Hypertens 2002;4:266
41 Salt-Sensitivity of BP Definition: BP from high-to-low or BP from low-to-high Na intake (slow dietary or rapid iv) AA hypertensive 75-80% White hypertensive 55-60% All normotensive 35%
42 Prognosis of SS in humans Kaplan-Meier curves for normotensive (N) or hypertensive (H) subjects, either salt-sensitive (S) or resistant (R) Weinberger et al. Hypertension 2001;37:429
43 Projected effects of Dietary Salt Reduction on Future Cardiovascular Disease Reducing dietary salt by 3 gm (1200 mg Na) would reduce annual new cases of: CHD by ,000, stroke by 32-66,000 and MI by 54-99,000; with overall decrease in deaths from any cause by 44-92,000. Higher risk groups benefit more: Blacks in all, Women in stroke, Older in CHD, Younger in mortality reductions. Overall annual savings of ,000 QALYs and $10 $24,000,000,000 (BILLIONS!) in US healthcare costs Bibbins-Domingo et al. NEJM 2010;362:590
44
45 Renin Profiling, Clinical Correlates and Selection of Therapy High PRA (15-18%) Normal (50-55%) Low (30-35%) Young Middle-aged Old Fair Skinned Darker Skinned Sympathetic Activity Obesity / Diabetes Diuretics -blockers Calcium blockers ACE-inhibitors a1 antagonists AngII-receptor DRI?
46 Resistant Hypertension Defined as BP not at goal despite good doses of three different (classes of) drugs, one of which is a diuretic. More common in elderly, obese, salt-lovers, diabetics, those with CKD or LVH More frequent in women than men, blacks than whites, southeast [ stroke belt ] Rule out extrinsic causes / noncompliance / white coat [ABPM or home BP <135/85] AHA statement. Hypertension 2008;51:1503
47 Extrinsic Hyperadrenergic Syndromes Disorder Mechanism Comments Amphetamines Direct + Catechol Release Appetite Suppressant, Illicit OTC Diet Pills Direct Adrenergic 2-fold Dose Produces HTN MAO Inh/Tyramine Massive Catechol Release In Psychiatric Patients Cocaine Inhibit Catechol Reuptake Tox Screen Clonidine Rebound Activation Central SNS Non-Compliance Panic Disorder Activation Central SNS Hx Required for Dx
48 Other Drugs / Agents that Raise Blood Pressure NSAIDS [kidney transporter, Na - PGE2/I2] Oral contraceptives [minor, increase AoGT] Alcohol > 4 (men) / 2 (women) drinks per day Corticosteroids [aldosterone effect] Erythropoietin [interferes with NO - add nitrate] Black licorice [snuff / chewing tobacco] Herbals [ma huang / ephedra, e.g., Metabolife]
49 Secondary Causes of (R) Hypertension Sleep Apnea [snoring / witnessed apnea / daytime sleepiness] refer for sleep study Intrinsic renal disease [ egfr, abnormal UA, etc] should be seen by Nephrologist Hyperaldosteronism [unexpected low K, hi CO2] screen with aldo:pra (specific only) Renal artery stenosis [bruit anywhere, PAD or CAD] MRA / renal Doppler / CT angiogram
50 RARE Causes of (R) Hypertension Pheochromocytoma [paroxysms / pale sweat / piloerection] pl metanephrines / clonidine test Cushing s disease [moon facies, etc] screening cortisol, dexamethasone-suppression test Hyperparathyroidism [hi Ca] screen with good ipth assay Aortic coarctation [DBP >10 between arms / leg] MRA / CT angiogram Intracranial tumor
51 Conclusions for Hypertension in Primary Care Most essential hypertensives are saltsensitive All patients with essential hypertension must be advised to reduce salt intake No essential hypertensive patient should be diagnosed as resistant if there is no diuretic in the treatment regimen If you can t control it, refer (HTN,, )
Combination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationManagement of Hypertension. Ahmed El Hawary MD Suez Canal University
Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and
More informationHypertension Management Focus on new RAAS blocker. Disclosure
Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationStrategies for Managing Hypertension
Strategies for Managing Hypertension by Marsha K. Millonig, MBA, RPh President,Catalyst Enterprises, LLC E.L.F. Publications, Inc. is accredited by the Accreditation Council for Pharmacy Education as a
More informationApproach to patient with hypertension. Dr. Amitesh Aggarwal
Approach to patient with hypertension Dr. Amitesh Aggarwal Definition A systolic blood pressure ( SBP) >139 mmhg and/or A diastolic (DBP) >89 mmhg. Based on the average of two or more properly measured,
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationHypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati
CHAPTER-I CARDIOVASCULAR SYSTEM Hypertension SUB: PHARMACOTHERAPEUTICS-I CODE:T0820006 Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati Hypertension
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationManagement of Hypertension in Women
Management of Hypertension in Women Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 1, 2013 Declaration of full disclosure: No conflict of interest (I have never been
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationHypertension. Most important public health problem in developed countries
Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,
More informationHypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations
Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Gerald W. Smetana, M.D., MACP Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine
More informationWhat s all the Fuss?
HYPERTENSION: What s all the Fuss? Presenter name: Presenter title: Department: Institute Marc A. Pohl, MD Ray W. Gifford Chair in Hypertension, and Head, Section of Clinical Hypertension Nephrology and
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationIntroduction. Factors affecting blood pressure: 1-COP = HR X SV mainly affect SBP. 2-TPR = diameter of arterioles X viscosity of blood affect DBP
Introduction Hypertension is a persistent elevation of blood pressure above 140 / 90 mmhg for more than three sitting. (0ptimal level
More informationDiversity and HTN: Approaches to optimal BP control in AfricanAmericans
Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Quinn Capers, IV, MD, FACC, FSCAI Assistant Professor of Medicine Associate Dean for Admissions Do Racial Differences Really Exist
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationManagement of Hypertension in the Diabetic Patient:
Management of Hypertension in the Diabetic Patient: Nicolas W. Shammas, MS, MD Research Director, Cardiovascular Medicine, PC Presentation Objectives To review: The relationship between HTN, insulin resistance
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationObjectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence
JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician
More informationΣτόχοι αρτηριακής πίεσης σε ειδικούς πληθυσµούς και επιλογή φαρµάκων
Στόχοι αρτηριακής πίεσης σε ειδικούς πληθυσµούς και επιλογή φαρµάκων Εύα Καρπάνου Δ/ντρια Αντιυπερτασικού Ιατρείου Α ΚΚ Ωνάσειου ΚΚ Θεσσαλονίκη, 14/2/13 Η µελέτη δεν υποστηρίχθηκε από φαρµακευτικές εταιρείες
More informationCOMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC
COMPLEX HYPERTENSION Anita Ralstin, FNP-BC Next Step Health Consultant, LLC Incidence Of Hypertension About 70 million American adults have high blood pressure. About 33% of the population Only 52% have
More informationHypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationHypertension in the very old. Objectives: Clinical Perspective
Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical
More informationDiagnosis and treatment of hypertension. Kari Nelson, MD MSHS Division of General Internal Medicine VA Puget Sound, University of Washington
Diagnosis and treatment of hypertension Kari Nelson, MD MSHS Division of General Internal Medicine VA Puget Sound, University of Washington Outline Epidemiology Diagnosis Evaluation of individuals with
More informationManagement of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University
Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationHypertension and Diabetes Will Controversies Help Our Patients? Insights of JNC Report Jorge De Jesús MD FACE
Hypertension and Diabetes Will Controversies Help Our Patients? Insights of JNC8 2013 Report Jorge De Jesús MD FACE Disclosures Dr Jorge De Jesús has received honorariums as speaker for the following pharmaceutical
More informationWe are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationDr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None
Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/
More informationALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,
More informationCONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL
CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL Douglas G. Kelling Jr., MD Carmella Gismondi-Eagan, MD, FACP George C. Monroe, III, MD Revised, April 8, 2012 The information contained in this protocol
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationHow to Manage Resistant Hypertension Min Su Hyon, MD
How to Manage Resistant Hypertension Min Su Hyon, MD Cardiovascular Medicine, Internal Medicine Soonchunhyang University College of Medicine Definition Resistant to conventional medical therapy Definition
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationDifficult to Control HTN: It is not all the same. Structured approach to evaluation and treatment
Difficult to Control HTN: It is not all the same. Structured approach to evaluation and treatment Dmitri Vasin M.D. Nephrologist and ASH certified clinical hypertension specialist Bremerton, WA, USA Johnson
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationGetting BP to goal: Virginia L. Hood MB.BS, MPH, FACP
Getting BP to goal: Virginia L. Hood MB.BS, MPH, FACP Objectives: Outline pathophysiological processes that sustain high BP Design individual treatment strategies for BP not at goal Facilitate patient
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationPractical Aspects of Hypertension: Simple Strategies to Help You and Your Patients Meet Guideline Blood Pressure Targets
Practical Aspects of Hypertension: Simple Strategies to Help You and Your Patients Meet Guideline Blood Pressure Targets Robert J. Herman University of Calgary herman@ucalgary.ca Conflict of Interest Disclosure
More informationHypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN
Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups Lisa Ivy APRN The 2017 Guideline is an Update to JNC7 New information regarding BP related risk of CVD Ambulatory BP monitoring
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationSection 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationWhat in the World is Functional Medicine?
What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationHypertension in Clinical Practice. Abeer Al Saweer, MBBS, Arab Board*
1 Bahrain Medical Bulletin, Vol. 33, No. 1, March 2011 Education-Family Physician Corner Hypertension in Clinical Practice Abeer Al Saweer, MBBS, Arab Board* The global incidence of hypertension is growing.
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationBlood Pressure. Michelle Bertram- Nephrology- OBH
Blood Pressure Michelle Bertram- Nephrology- OBH Hypertension- how common? 29-30% white adults 46-51% uncontrolled Diagnosis Two or more properly measured BP s after an initial screen NICE guidelines also
More informationBlood Pressure Treatment in 2018
Blood Pressure Treatment in 2018 Jay D. Geoghagan, MD, FACC Disclosures: None 1 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management
More informationPharmacologic Management of Hypertension
Current Concepts In Management of Fernando Vega, MD Secondary - Definition Renovascular Disease (The kidney doesn t get impressed by blood pressure) Renovascular stenosis Renal artery stenosis Fibromuscular
More information